A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer

British Journal of Cancer

Volumn 89, Issue 8, 2003, Pages 1418-1422

  Madhusudan, S ^a   Protheroe, A ^a   Propper, D ^a,h   Han, C ^a   Corrie, P ^b   Earl, H ^b   Hancock, B ^c   Vasey, P ^d   Turner, A ^e   Balkwill, F ^f   Hoare, S ^f   Harris, A L ^a,g  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Bryostatin 1; Kidney cancer; Phase II trial; Protein kinase C

Indexed keywords

BRYOSTATIN 1; CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASSAY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FATALITY; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; DYSKINESIA; ENZYME ACTIVITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEART PALPITATION; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPONATREMIA; IMMUNOMODULATION; INFLAMMATION; INSOMNIA; KIDNEY CANCER; KIDNEY FAILURE; LYMPHOCYTOPENIA; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; TONGUE; ULCER; VISUAL IMPAIRMENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; KIDNEY NEOPLASMS; LACTONES; MACROLIDES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0242491493     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601321     Document Type: Article

References (33)

1. Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T (2001) Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 11: 183-188
2. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002) Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2: 311-315
3. Brockstein B, Samuels B, Humerickhouse R, Arietta R, Fishkin P, Wade J, Sosman J, Vokes EE (2001) Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 19: 249-254
4. Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43: 158-163
5. Fowler L, Everitt J, Stevens JL, Jaken S (1998) Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha-and gamma-adducin during renal tumor progression. Cell Growth Differ 9: 405-413
6. Glaspy JA (2002) Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29: 41-46
7. Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D, Kraft AS (1999) Treatment of patients with metastatic melanoma with bryostatin-1-a phase II study. Melanoma Res 9: 599-606
8. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD (1998) Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 4: 611-618
9. Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR (2003) Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 9: 109-114
10. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR (1995) A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72: 461-468
11. Kaubisch A, Kelsen DP, Saltz L, Kemeny N, O'Reilly E, Ilson D, Endres, Barazzuol J, Schwartz GKA (1999) A phase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumours. Proc Am Soc Clin Oncol 18: 166a
12. Kraft AS, William F, Pettit GR, Lilly MB (1989) Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 49: 1287-1293
13. Lilly M, Tompkins C, Brown C, Pettit G, Kraft A (1990) Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res 50: 5520-5525
14. Mathew A, Devesa SS, Fraumeni Jr JF, Chow WH (2002) Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11: 171-178
15. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM (2000) The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 6: 4950-4956
16. Mohr H, Pettit GR, Plessing-Menze A (1987) Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology 175: 420-430
17. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R (2000) A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89: 615-618
18. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D (1997) The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272: 27509-27512
19. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49: 33-64, 1.
20. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F (1993) Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85: 1812-1818
21. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR (1993) A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418-424
22. Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78: 1337-1341
23. Rosenthal MA, Oratz R, Liebes L, Cahr MH, Muggia FM (1999) Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies. Proc Am Soc Clin Oncol 18: 227a
24. Salgado R, Benoy I, Weytjens R, Van Bockstaele D, Van Marck E, Huget P, Hoylaerts M, Vermeulen P, Dirix LY (2002) Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 87: 1437-1444
25. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80: 892-897
26. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51: 682-687
27. Stanwell C, Gescher A, Bradshaw TD, Pettit GR (1994) The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer 56: 585-592
28. Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, Braybrook J, Caponigro F, Hutchison C, Twelves C, Man A, Fabbro D, Harris A, Balkwill F (1999) The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res 59: 3980-3984
29. Tuttle TM, Inge TH, Wirt CP, Frank JL, McCrady CM, Bear HD (1992) Bryostatin 1 activates T cells that have antitumor activity. J Immunother 12: 75-81
30. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56-62
31. Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM (2000) Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 6: 825-828
32. Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M (1999) A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res 5: 2344-2348
33. Wender PA, Hinkle KW, Koehler MF, Lippa B (1999) The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Med Res Rev 19: 388-407